Talal Andrew H, George Saliyah J, Talal Lillian A, Dharia Arpan, Ventuneac Ana, Baciewicz Gloria, Perumalswami Ponni V, Dickerson Suzanne S
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University at Buffalo, State University of New York, 875 Ellicott Street, Suite 6090, Buffalo, NY, 14203, USA.
Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Res Involv Engagem. 2023 Aug 2;9(1):63. doi: 10.1186/s40900-023-00474-x.
People who use drugs (PWUD) have difficulty participating in clinical research. We evaluated approaches to engage PWUD in clinical research, using facilitated telemedicine for hepatitis C virus (HCV) care as an example.
We analyzed stakeholder interview transcripts and study-related data (i.e., progress reports, meeting minutes) from interrelated studies to understand engagement experiences at the patient, site, and organizational levels. Stakeholders include patient-participants, opioid treatment program (OTP) staff and administrators, and research team members involved in HCV management through facilitated telemedicine integrated into OTPs.
Three themes emerged. Initially, the research team sought understanding of the unique culture and community of each OTP (Theme 1). The team built trusting relationships through education, communication, and feedback (Theme 2). Finally, the research team enhanced collaborative care and incorporated the patients' voice to improve health outcomes (Theme 3). Patient-participants and OTP staff endorsed the integrated HCV care approach. Engagement practices are summarized as the CREATE framework (C = culture, R = respect, E = educate, A = advantage, T = trust, E = endorse).
PWUD engagement in clinical research is maximized by building trusting relationships with open communication channels. Understanding the community, demonstrating respect, and augmenting knowledge are foundational for engaging PWUD in clinical research. These practices are transferable to engagement of PWUD in clinical research broadly.
吸毒者参与临床研究存在困难。我们以利用远程医疗辅助丙型肝炎病毒(HCV)治疗为例,评估了促使吸毒者参与临床研究的方法。
我们分析了来自相关研究的利益相关者访谈记录和研究相关数据(即进展报告、会议记录),以了解患者、研究点和组织层面的参与情况。利益相关者包括患者参与者、阿片类药物治疗项目(OTP)的工作人员和管理人员,以及通过整合到OTP中的远程医疗辅助参与HCV管理的研究团队成员。
出现了三个主题。首先,研究团队试图了解每个OTP独特的文化和社区(主题1)。团队通过教育、沟通和反馈建立信任关系(主题2)。最后,研究团队加强协作式护理并纳入患者的意见以改善健康结果(主题3)。患者参与者和OTP工作人员认可整合的HCV护理方法。参与实践总结为CREATE框架(C = 文化,R = 尊重,E = 教育,A = 优势,T = 信任,E = 认可)。
通过建立开放沟通渠道的信任关系,可最大限度地促使吸毒者参与临床研究。了解社区、表达尊重和增加知识是促使吸毒者参与临床研究的基础。这些实践可广泛应用于促使吸毒者参与临床研究。